Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 17.9% on Thursday . The stock traded as high as C$0.33 and last traded at C$0.33. 1,140,716 shares changed hands during trading, an increase of 72% from the average session volume of 663,769 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Up 7.1 %
The firm has a 50 day simple moving average of C$0.13 and a two-hundred day simple moving average of C$0.09. The stock has a market capitalization of C$32.67 million, a P/E ratio of -18.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Best Aerospace Stocks Investing
- Bloom Energy: Powering the Future With Decentralized Energy
- Industrial Products Stocks Investing
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Technology Stocks Explained: Here’s What to Know About Tech
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
